Syneos Health Inc (NASDAQ:SYNH) Expected to Post Earnings of $1.01 Per Share

Equities analysts expect that Syneos Health Inc (NASDAQ:SYNH) will report $1.01 earnings per share for the current quarter, Zacks reports. Six analysts have made estimates for Syneos Health’s earnings. The highest EPS estimate is $1.03 and the lowest is $0.99. Syneos Health posted earnings per share of $0.95 during the same quarter last year, which would suggest a positive year over year growth rate of 6.3%. The business is scheduled to report its next earnings results on Monday, March 16th.

On average, analysts expect that Syneos Health will report full year earnings of $3.21 per share for the current fiscal year, with EPS estimates ranging from $3.19 to $3.23. For the next year, analysts anticipate that the company will report earnings of $3.63 per share, with EPS estimates ranging from $3.60 to $3.68. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Syneos Health.

Syneos Health (NASDAQ:SYNH) last released its earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.82 by $0.05. Syneos Health had a return on equity of 10.13% and a net margin of 1.86%. The business had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same period last year, the business posted $0.75 earnings per share. The business’s revenue for the quarter was up 5.6% on a year-over-year basis.

Several equities analysts have recently weighed in on the company. ValuEngine upgraded Syneos Health from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Jefferies Financial Group lifted their price target on Syneos Health from $62.00 to $65.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. KeyCorp lifted their price target on Syneos Health from $63.00 to $65.00 and gave the company an “overweight” rating in a research report on Tuesday, September 3rd. UBS Group lifted their price target on Syneos Health from $53.50 to $57.00 and gave the company a “neutral” rating in a research report on Thursday, August 29th. Finally, Zacks Investment Research cut Syneos Health from a “buy” rating to a “hold” rating and set a $55.00 price target for the company. in a research report on Tuesday, September 10th. Five analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $59.50.

Several hedge funds and other institutional investors have recently made changes to their positions in SYNH. BB&T Corp grew its position in shares of Syneos Health by 8.1% in the second quarter. BB&T Corp now owns 8,749 shares of the company’s stock valued at $448,000 after purchasing an additional 656 shares in the last quarter. Arizona State Retirement System grew its position in Syneos Health by 1.6% during the second quarter. Arizona State Retirement System now owns 44,429 shares of the company’s stock worth $2,270,000 after buying an additional 697 shares in the last quarter. Financial Gravity Wealth Inc. purchased a new position in Syneos Health during the second quarter worth about $29,000. SG Americas Securities LLC grew its position in Syneos Health by 41.1% during the second quarter. SG Americas Securities LLC now owns 80,482 shares of the company’s stock worth $4,112,000 after buying an additional 23,454 shares in the last quarter. Finally, First Trust Advisors LP purchased a new position in Syneos Health during the second quarter worth about $5,423,000.

NASDAQ:SYNH traded up $0.22 during trading hours on Friday, reaching $55.53. The stock had a trading volume of 8,663 shares, compared to its average volume of 316,884. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.03 and a current ratio of 1.03. The stock has a 50 day simple moving average of $52.55 and a 200 day simple moving average of $50.73. Syneos Health has a 12-month low of $36.26 and a 12-month high of $56.34. The stock has a market cap of $5.76 billion, a P/E ratio of 21.27, a price-to-earnings-growth ratio of 1.88 and a beta of 1.50.

Syneos Health Company Profile

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

See Also: Price-Sales Ratio

Get a free copy of the Zacks research report on Syneos Health (SYNH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.